LIGAND PHARMACEUTICALS INCORPORATED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 71.42 USD | +2.19% |
|
+0.59% | 0.00% |
Chart calendar Ligand Pharmaceuticals Incorporated
97c7ffabd86998efb9491e.Vcj4sK19-M7el28h7-wdgQSylZJ0aj20j_seBHRUWaY.Oo6A2dwasICQ2EJz25xJ83L-oc1NKxDXy7ZXM0J5K-APn8qE6jqxjIH5Xw~c305f586159f2ebd9a5ab811a8b3901a
Upcoming events on Ligand Pharmaceuticals Incorporated
Past events on Ligand Pharmaceuticals Incorporated
| 14/03/2024 08:15 pm | Barclays Global Healthcare Conference |
| 27/02/2024 07:00 pm | Q4 2023 Earnings Call |
| 27/02/2024 05:30 pm | Q4 2023 Earnings Release |
| 12/12/2023 09:00 pm | Investor and Analyst Day |
| 09/11/2023 03:00 am | Q3 2023 Earnings Call |
| 09/11/2023 02:31 am | Q3 2023 Earnings Release |
| 12/09/2023 09:30 am | H.C. Wainwright 25th Annual Global Investment Conference |
| 09/08/2023 02:00 am | Q2 2023 Earnings Call |
| 09/08/2023 01:31 am | Q2 2023 Earnings Release |
| 09/06/2023 09:00 pm | Annual General Meeting |
| 05/05/2023 02:00 am | Q1 2023 Earnings Call |
| 05/05/2023 01:31 am | Q1 2023 Earnings Release |
| 23/02/2023 03:00 am | FY 2022 Earnings Call |
| 23/02/2023 02:31 am | FY 2022 Earnings Release |
| 13/12/2022 09:30 pm | Analyst and Investor Day |
| 09/12/2022 06:30 pm | San Antonio Breast Cancer Symposium - Poster No: P6-09-01 |
| 09/12/2022 06:30 pm | San Antonio Breast Cancer Symposium - Poster No: P6-09-02 |
| 09/12/2022 04:30 am | San Antonio Breast Cancer Symposium - Poster No: P5-05-02 |
| 09/12/2022 04:30 am | San Antonio Breast Cancer Symposium - Poster No: P5-05-04 |
| 08/11/2022 03:00 am | Q3 2022 Earnings Call |
Past dividends on Ligand Pharmaceuticals Incorporated
| 02/11/2022 | 0 USD |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 120 118 1.54% | 186 173 7.72% | 277 270 2.73% | 196 184 6.55% | 131 129 1.88% | 137 |
|
EBITDA Million USD | Released Forecast Spread | 62,5 71,8 -12.92% | 80,0 76,0 5.23% | 165 157 5.05% | 87,8 92,7 -5.33% | 70,3 84,3 -16.62% | 103 |
|
EBIT Million USD | Released Forecast Spread | -5,72 7,73 -174.02% | 25,8 29,9 -13.58% | 78,9 65,7 20.04% | 3,04 -6,02 150.48% | 11,9 10,7 11.81% | 23,2 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 797 797 -0.08% | -10,5 -5,29 -99.33% | 47,3 65,2 -27.46% | 36,0 -16,9 313.18% | 63,7 42,3 50.39% | 36,5 |
|
Net income Million USD | Released Forecast Spread | 629 636 -1.03% | -2,99 -2,46 -21.36% | 57,6 71,9 -19.9% | -33,4 -12,9 -158.89% | 52,2 32,0 62.92% | 28,5 |
|
EPS USD | Released Forecast Spread | 31,9 32,9 -3.05% | -0,18 -0,13 -44% | 3,34 4,25 -21.37% | -1,98 -0,62 -221.95% | 2,94 1,91 54.2% | 1,67 |
| Announcement Date | 06/02/20 | 03/02/21 | 17/02/22 | 22/02/23 | 27/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 72,5 65,1 11.35% | 45,7 34,2 33.56% | 57,4 37,7 52.16% | 66,1 38,3 72.41% | 50,4 39,6 27.12% | 44,0 33,5 31.1% | 26,4 25,7 2.46% | 32,9 27,2 20.73% | 28,1 25,6 9.58% | 27,9 | 33,2 | 35,9 | 40,4 |
|
EBITDA Million USD | Released Forecast Spread | 34,8 34,1 2.05% | 11,5 11,2 2.5% | 22,3 4,58 386.92% | 25,0 12,0 108.22% | 16,1 29,0 -44.58% | 28,2 27,4 2.99% | 14,7 17,3 -14.81% | 15,0 16,0 -6.3% | 10,7 14,2 -25.02% | 16,3 | 24,4 | 29,1 | 33,4 |
|
EBIT Million USD | Released Forecast Spread | 12,7 12,0 6.13% | -9,31 -12,2 23.96% | -0,47 -21,4 97.81% | 0,64 -12,1 105.24% | -20,1 3,14 -739.35% | 14,2 0,28 4968.69% | -1,98 -1,29 -53.6% | -0,12 -1,97 93.79% | -3,36 -3,21 -4.55% | -1,51 | 4,37 | 8,33 | 12,0 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -7,03 8,60 -181.73% | -20,1 -15,1 -33.55% | -0,64 -16,9 96.24% | 0,86 -10,2 108.4% | 24,1 3,03 696.61% | 55,5 1,17 4632.51% | 3,17 3,29 -3.54% | -15,3 -2,26 -580.26% | 17,1 -1,71 1102.17% | 3,04 | 8,18 | 11,0 | 14,3 |
|
Net income Million USD | Released Forecast Spread | -4,97 7,05 -170.49% | -15,4 -11,8 -30.89% | -0,90 -13,0 93.11% | 0,40 -8,44 104.79% | -17,5 2,71 -746.08% | 41,9 -1,49 2912.22% | 2,29 1,80 26.94% | -12,8 -3,72 -243.96% | 18,2 -1,16 1666.92% | 2,36 | 6,24 | 8,59 | 11,4 |
|
EPS USD | Released Forecast Spread | -0,30 0,44 -168.81% | -0,91 -0,58 -57.99% | -0,05 -0,62 91.9% | 0,02 -0,48 104.19% | -1,04 0,32 -430.16% | 2,33 0,18 1194.44% | 0,13 -0,05 388.89% | -0,74 0,05 -1685.6% | 1,03 0,07 1371.43% | 0,23 | 0,40 | 0,49 | 0,55 |
| Announcement Date | 17/02/22 | 04/05/22 | 08/08/22 | 07/11/22 | 22/02/23 | 04/05/23 | 08/08/23 | 08/11/23 | 27/02/24 | - | - | - | - |
More events
Past sector events for Ligand Pharmaceuticals Incorporated
| Today | BAUSCH HEALTH COMPANIES INC.: Q1 2024 Earnings Release |
| Today | AMGEN INC.: Q1 2024 Earnings Release |
| 02/05/2024 01:35 am | CORCEPT THERAPEUTICS INCORPORATED: Q1 2024 Earnings Release |
| 02/05/2024 01:35 am | JAZZ PHARMACEUTICALS PLC: Q1 2024 Earnings Release |
| 01/05/2024 04:15 pm | PFIZER, INC.: Q1 2024 Earnings Release |
| 01/05/2024 12:30 pm | HALEON PLC: Q1 2024 Sales and Revenue Release - Trading Statement |
| 01/05/2024 11:30 am | GSK PLC: Q1 2024 Earnings Release |
| 01/05/2024 | INNOVIVA, INC.: Q1 2024 Earnings Release (Projected) |
| 01/05/2024 | PACIRA BIOSCIENCES, INC.: Q1 2024 Earnings Release (Projected) |
| 01/05/2024 | EYEPOINT PHARMACEUTICALS, INC.: Q1 2024 Earnings Release (Projected) |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- LGND Stock
- Calendar Ligand Pharmaceuticals Incorporated
